Prospective validation of the endurance shuttle walking test in the context of bronchodilation in COPD

European Respiratory Journal

Volumn 44, Issue 5, 2014, Pages 1166-1176

  Borel, Benoit ^a,b   Pepin, Véronique ^c   Mahler, Donald A ^d   Nadreau, Éric ^a   Maltais, François ^a  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ DE LIMOGES   (France)

^c HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^d DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTICASONE PROPIONATE PLUS SALMETEROL XINAFOATE; PLACEBO; TIOTROPIUM BROMIDE; ANDROSTANE DERIVATIVE; BRONCHODILATING AGENT; FLUTICASONE; SCOPOLAMINE DERIVATIVE;

ADAPTATION; ADULT; ARTERIAL OXYGEN SATURATION; ARTICLE; BRONCHODILATATION; CARDIOPULMONARY FUNCTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DOUBLE BLIND PROCEDURE; ENDURANCE; ENDURANCE SHUTTLE WALKING TEST; EXERCISE TEST; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT REPEATABILITY; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; OPEN STUDY; PARALLEL DESIGN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULSE OXIMETRY; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; SINGLE DRUG DOSE; TASK PERFORMANCE; TEST RETEST RELIABILITY; TIME; VALIDATION STUDY; WALKING; AGED; ANTHROPOMETRY; CLINICAL TRIAL; EXERCISE TOLERANCE; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES;

AGED; ANDROSTADIENES; ANTHROPOMETRY; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REPRODUCIBILITY OF RESULTS; SCOPOLAMINE DERIVATIVES; WALKING;

EID: 84926488045     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00024314     Document Type: Article

References (37)

1. Martinez FJ, Foster G, Curtis JL, et al. Predictors of mortality in patients with emphysema and severe airflow obstruction. Am J Respir Crit Care Med 2006; 173: 1326-1334.
2. Oga T, Nishimura K, Tsukino M, et al. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: Role of exercise capacity and health status. Am J Respir Crit Care Med 2003; 167: 544-549.
3. O'Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23: 832-840.
4. Laviolette L, Bourbeau J, Bernard S, et al. Assessing the impact of pulmonary rehabilitation on functional status in COPD. Thorax 2008; 63: 115-121.
5. Maltais F, Mahler DA, Pepin V, et al. Effect of fluticasone propionate/salmeterol plus tiotropium versus tiotropium on walking endurance in COPD. Eur Respir J 2013; 42: 539-541.
6. Solway S, Brooks D, Lacasse Y, et al. A qualitative systematic overview of the measurement properties of functional walk tests used in the cardiorespiratory domain. Chest 2001; 119: 256-270.
7. Eaton T, Young P, Nicol K, et al. The endurance shuttle walking test: A responsive measure in pulmonary rehabilitation for COPD patients. Chron Respir Dis 2006; 3: 3-9.
8. Bedard ME, Brouillard C, Pepin V, et al. Tiotropium improves walking endurance in COPD. Eur Respir J 2012; 39: 265-271.
9. Brouillard C, Pepin V, Milot J, et al. Endurance shuttle walking test: Responsiveness to salmeterol in COPD. Eur Respir J 2008; 31: 579-584.
10. Pepin V, Saey D, Laviolette L, et al. Exercise capacity in chronic obstructive pulmonary disease: Mechanisms of limitation. COPD 2007; 4: 195-204.
11. Pepin V, Saey D, Whittom F, et al. Walking versus cycling: sensitivity to bronchodilation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172: 1517-1522.
12. Revill SM, Morgan MD, Singh SJ, et al. The endurance shuttle walk: A new field test for the assessment of endurance capacity in chronic obstructive pulmonary disease. Thorax 1999; 54: 213-222.
13. Pepin V, Laviolette L, Brouillard C, et al. Significance of changes in endurance shuttle walking performance. Thorax 2011; 66: 115-120.
14. Singh SJ, Morgan MD, Scott S, et al. Development of a shuttle walking test of disability in patients with chronic airways obstruction. Thorax 1992; 47: 1019-1024.
15. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307-310.
16. Lee J, Koh D, Ong CN. Statistical evaluation of agreement between two methods for measuring a quantitative variable. Comput Biol Med 1989; 19: 61-70.
17. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation. Med Care 2003; 41: 582-592.
18. Guyatt GH, Osoba D, Wu AW, et al. Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002; 77: 371-383.
19. Revill SM, Noor MZ, Butcher G, et al. The endurance shuttle walk test: An alternative to the six-minute walk test for the assessment of ambulatory oxygen. Chron Respir Dis 2010; 7: 239-245.
20. Pepin V, Brodeur J, Lacasse Y, et al. Six-minute walking versus shuttle walking: Responsiveness to bronchodilation in chronic obstructive pulmonary disease. Thorax 2007; 62: 291-298.
21. Revill SM, Williams J, Sewell L, et al. Within-day repeatability of the endurance shuttle walk test. Physiotherapy 2009; 95: 140-403.
22. O'Donnell DE, Travers J, Webb KA, et al. Reliability of ventilatory parameters during cycle ergometry in multicentre trials in COPD. Eur Respir J 2009; 34: 866-874.
23. Muller R, Buttner P. A critical discussion of intraclass correlation coefficients. Stat Med 1994; 13: 2465-2476.
24. Weir JP. Quantifying test-retest reliability using the intraclass correlation coefficient and the SEM. J Strength Cond Res 2005; 19: 231-240.
25. Borel B, Provencher S, Saey D, et al. Responsiveness of various exercise-Testing protocols to therapeutic interventions in COPD. Pulm Med 2013; 2013: 410748.
26. Puhan MA, Mador MJ, Held U, et al. Interpretation of treatment changes in 6-minute walk distance in patients with COPD. Eur Respir J 2008; 32: 637-643.
27. Schunemann HJ, Griffith L, Jaeschke R, et al. Evaluation of the minimal important difference for the feeling thermometer and the St. George's Respiratory Questionnaire in patients with chronic airflow obstruction. J Clin Epidemiol 2003; 56: 1170-1176.
28. Puhan MA, Chandra D, Mosenifar Z, et al. The minimal important difference of exercise tests in severe COPD. Eur Respir J 2011; 37: 784-790.
29. Jones PW, Beeh KM, Chapman KR, et al. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med 2014; 189: 250-255.
30. Redelmeier DA, Bayoumi AM, Goldstein RS, et al. Interpreting small differences in functional status: The six minute walk test in chronic lung disease patients. Am J Respir Crit Care Med 1997; 155: 1278-1282.
31. Dyer CA, Singh SJ, Stockley RA, et al. The incremental shuttle walking test in elderly people with chronic airflow limitation. Thorax 2002; 57: 34-38.
32. Dyer F, Marriner P, Cheema K, et al. Is a practice incremental shuttle walk test really necessary? Chron Respir Dis 2011; 8: 201-205.
33. Eiser N, Willsher D, Dore CJ. Reliability, repeatability and sensitivity to change of externally and self-paced walking tests in COPD patients. Respir Med 2003; 97: 407-414.
34. Arnardottir RH, Emtner M, Hedenstrom H, et al. Peak exercise capacity estimated from incremental shuttle walking test in patients with COPD: A methodological study. Respir Res 2006; 7: 127.
35. McKeough ZJ, Leung RW, Alison JA. Shuttle walk tests as outcome measures: Are two incremental shuttle walk tests and two endurance shuttle walk tests necessary? Am J Physl Med Rehabil 2011; 90: 35-39.
36. Hill K, Dolmage TE, Woon L, et al. Comparing peak and submaximal cardiorespiratory responses during field walking tests with incremental cycle ergometry in COPD. Respirology 2012; 17: 278-284.
37. Zainuldin R, Mackey MG, Alison JA. Prescription of walking exercise intensity from the incremental shuttle walk test in people with chronic obstructive pulmonary disease. Am J Physl Med Rehabil 2012; 91: 592-600.